| Craig Desmond Rhyne, MD | |
|
3509 22nd St, Lubbock, TX 79410-1307 | |
| (806) 799-7928 | |
| (806) 788-8500 |
| Full Name | Craig Desmond Rhyne |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 3509 22nd St, Lubbock, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306849187 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | F4428 (Texas) | Primary |
| Entity Name | Covenant Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376598904 PECOS PAC ID: 6901889393 Enrollment ID: O20040608000563 |
News Archive
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
Large randomized clinical trials can uncover biomarkers that indicate which cancer treatments are likely to work best for individual patients. But it's been challenging to find these biomarkers in rarer cancers where such robust data aren't available.
Targeted Genetics Corporation (the "Company") today announced that it has determined that the expense and management attention required for NASDAQ Capital Market and Securities and Exchange Commission ("SEC") compliance outweigh the benefits for the Company and its shareholders at this time.
The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.
ENT and Allergy Associates LLP (ENTA) is pleased to announce a significant expansion of their practice, with the opening of 2 new locations-in Edison and Old Bridge, New Jersey. These State-of-the-art medical offices will serve the growing population of Middlesex County, with physicians and clinical staff providing full service Otolaryngology, Audiology and Allergy medical services. This expansion includes the merging of Dr. Gerald Scott's existing Edison and Old Bridge practice into ENTA, effective immediately.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Craig Desmond Rhyne, MD 3509 22nd St, Lubbock, TX 79410-1307 Ph: (806) 799-7928 | Craig Desmond Rhyne, MD 3509 22nd St, Lubbock, TX 79410-1307 Ph: (806) 799-7928 |
News Archive
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
Large randomized clinical trials can uncover biomarkers that indicate which cancer treatments are likely to work best for individual patients. But it's been challenging to find these biomarkers in rarer cancers where such robust data aren't available.
Targeted Genetics Corporation (the "Company") today announced that it has determined that the expense and management attention required for NASDAQ Capital Market and Securities and Exchange Commission ("SEC") compliance outweigh the benefits for the Company and its shareholders at this time.
The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.
ENT and Allergy Associates LLP (ENTA) is pleased to announce a significant expansion of their practice, with the opening of 2 new locations-in Edison and Old Bridge, New Jersey. These State-of-the-art medical offices will serve the growing population of Middlesex County, with physicians and clinical staff providing full service Otolaryngology, Audiology and Allergy medical services. This expansion includes the merging of Dr. Gerald Scott's existing Edison and Old Bridge practice into ENTA, effective immediately.
› Verified 7 days ago
Ted W Allen, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8560 | |
Sammy Anthony Deeb, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3509 22nd St, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8500 | |
Monja L Proctor, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4102 22nd Pl, Lubbock, TX 79410 Phone: 806-725-0237 Fax: 806-725-1030 | |
Dr. Brittany Kay Bankhead, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-2373 Fax: 806-743-4354 | |
Adam Purtell, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-799-7928 Fax: 806-788-8560 | |
Dr. Gerald Lynn Woolam, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3611 22nd Pl, Lubbock, TX 79410 Phone: 806-771-2222 Fax: 806-771-2224 | |
Delphine Engel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-2370 Fax: 806-743-1475 |